Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
MDA awards over $21M in grants for advancing critical neuromuscular research

MDA awards over $21M in grants for advancing critical neuromuscular research

UNC Charlotte researcher improves lives of families and children affected by birth defects

UNC Charlotte researcher improves lives of families and children affected by birth defects

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

Committee recommends inclusion of genetic diseases in newborn screening program

Committee recommends inclusion of genetic diseases in newborn screening program

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Life Technologies' real-time PCR instrument available for IVD use in Europe

Life Technologies' real-time PCR instrument available for IVD use in Europe

Blocking RhoA enzyme increases survival in SMA mouse model

Blocking RhoA enzyme increases survival in SMA mouse model

New article sheds light on the costs and benefits of screening for SMA

New article sheds light on the costs and benefits of screening for SMA

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Reversing protein deficiency through gene therapy can improve SMA

Reversing protein deficiency through gene therapy can improve SMA

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

Spinal muscular atrophy screening, not cost effective

Spinal muscular atrophy screening, not cost effective

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

iPierian receives UK patent for induced pluripotent stem cell technology

iPierian receives UK patent for induced pluripotent stem cell technology

Simple, five minute saliva test to determine baby's risk for more than 100 life-threatening genetic diseases

Simple, five minute saliva test to determine baby's risk for more than 100 life-threatening genetic diseases

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

A novel approach for funding children's genetic disease research

A novel approach for funding children's genetic disease research